Len Schleifer, Regeneron CEO (Andrew Harnik/AP Images)
With 7 PD-(L)1s on the market, price competition hasn't been a factor. Will Regeneron be the first to ask for less?
In what seems like a counterintuitive strategy, seven drugs have piled in the anti-PD-(L)1 market so far, all at roughly the same list price. With no price competition to speak of, how do also-rans like Regeneron and Sanofi’s Libtayo differentiate themselves? Maybe try discounting, a top analyst muses.
In an open letter to Regeneron CEO Len Schleifer, Bernstein analyst Ronny Gal asked the New York drugmaker to be the first to discount its partnered Libtayo as more competitors pile into the field with no meaningful price competition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
